Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
First Claim
Patent Images
1. A method of enhancing libido in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof and an estrogen, provided said patient does not have vaginal atrophy.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to pharmaceutical compositions, kits and methods comprising combinations of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof and estrogens. The present invention also relates to pharmaceutical compositions, kits and methods comprising combinations of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof, estrogens and progestins.
-
Citations
12 Claims
-
1. A method of enhancing libido in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof and an estrogen, provided said patient does not have vaginal atrophy.
-
2. A method of enhancing libido in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof, an estrogen and a progestin, provided said patient does not have vaginal atrophy.
-
3. A method of treating hypoactive sexual desire disorder in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amonut of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof and an estrogen, provided said patient does not have vaginal atrophy.
-
4. A method of treating hypoactive sexual desire disorder in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof, an estrogen and a progestin, provided said patient does not have vaginal atrophy.
-
5. A method of treating sexual arousal disorder in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof and an estrogen, provided said patient does not have vaginal atrophy.
-
6. A method of treating sexual arousal disorder in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof, an estrogen and a progestin, provided said patient does not have vaginal atrophy.
-
7. A method of treating dyspareunia in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amonut of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof and an estrogen, provided said patient does not have vaginal atrophy.
-
8. A method of treating dyspareunia in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof, an estrogen and a progestin, provided said patient does not have vaginal atrophy.
-
9. A method of increasing the frequency and intensity of orgasms in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof and an estrogen, provided said patient does not have vaginal atrophy.
-
10. A method of increasing the frequency and intensity of orgasms in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof, an estrogen and a progestin, provided said patient does not have vaginal atrophy.
-
11. A method of treating vaginismus in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof and an estrogen, provided said patient does not have vaginal atrophy.
-
12. A method of treating vaginismus in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of (−
- )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmacologically acceptable acid addition salt thereof, an estrogen and a progestin, provided said patient does not have vaginal atrophy.
Specification